$450 Million is the total value of Avoro Capital Advisors LLC's 48 reported holdings in Q2 2016. The portfolio turnover from Q1 2016 to Q2 2016 was 56.8% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| TSRO | Buy | TESARO INC | $43,202,000 | +554.1% | 514,000 | +242.7% | 9.60% | +316.7% |
| LBIO | Buy | LION BIOTECHNOLOGIES INC | $35,142,000 | +121.4% | 4,338,557 | +38.8% | 7.81% | +41.0% |
| CPXX | Sell | CELATOR PHARMACEUTICALS INC. | $33,942,000 | +117.3% | 1,124,666 | -20.6% | 7.54% | +38.4% |
| BMRN | Buy | BIOMARIN PHARMACEUTICAL INC | $33,685,000 | +47.3% | 432,972 | +56.2% | 7.48% | -6.2% |
| BMY | Buy | BRISTOL MYERS SQUIBB CO. | $32,755,000 | +193.0% | 445,339 | +154.5% | 7.28% | +86.6% |
| SRPT | Buy | SAREPTA THERAPUTICS INC | $26,930,000 | +19.4% | 1,412,190 | +22.3% | 5.98% | -23.9% |
| NBIX | Buy | NEUROCRINE BIOSCIENCES INC | $23,149,000 | +44.4% | 509,330 | +25.7% | 5.14% | -8.0% |
| DERM | Buy | DERMIRA INC | $21,109,000 | +483.3% | 721,663 | +312.4% | 4.69% | +271.4% |
| FOLD | Buy | AMICUS THERAPEUTICS INC | $20,195,000 | -30.2% | 3,698,665 | +8.0% | 4.49% | -55.5% |
| IMMU | Buy | IMMUNOMEDICS INC | $19,852,000 | +656.0% | 8,556,957 | +714.6% | 4.41% | +381.6% |
| MDVN | Buy | MEDIVATION INC | $16,866,000 | +35.5% | 279,700 | +3.3% | 3.75% | -13.7% |
| GBT | Buy | GLOBAL BLOOD THERAPEEUTICS INC | $15,987,000 | +384.5% | 963,646 | +363.1% | 3.55% | +208.7% |
| AGEN | Buy | AGENUS INC | $12,554,000 | +25.7% | 3,099,838 | +29.1% | 2.79% | -19.9% |
| RLYP | New | RELYPSA INC | $11,346,000 | – | 613,300 | +100.0% | 2.52% | – |
| ACAD | New | ACADIA PHARMACEUTICALS INC | $10,696,000 | – | 329,500 | +100.0% | 2.38% | – |
| SRNE | Buy | SORRENTO THERAPEUTICS INC | $9,270,000 | +50.4% | 1,655,274 | +44.5% | 2.06% | -4.2% |
| TLGT | Buy | TELIGENT INC. | $9,211,000 | +103.2% | 1,290,000 | +39.5% | 2.05% | +29.5% |
| Buy | NEURODERM LTD | $9,051,000 | +19.3% | 557,003 | +3.6% | 2.01% | -24.0% | |
| GILD | Sell | GILEAD SCIENCES INC | $9,051,000 | -43.8% | 108,500 | -38.1% | 2.01% | -64.2% |
| VNDA | Sell | VANDA PHARMACEUTICALS INC | $7,940,000 | +11.1% | 709,579 | -17.0% | 1.76% | -29.2% |
| MRTX | Sell | MIRATI THERAPEUTICS INC | $6,633,000 | -77.9% | 1,214,833 | -13.5% | 1.47% | -85.9% |
| CASC | New | CASCADIAN THERAPEUTICS INC | $5,418,000 | – | 5,744,723 | +100.0% | 1.20% | – |
| CYTK | New | CYTOKINETICS INC. | $4,782,000 | – | 503,900 | +100.0% | 1.06% | – |
| AKBA | New | AKEBIA THERAPEUTICS INC | $4,652,000 | – | 621,873 | +100.0% | 1.03% | – |
| VCYT | Buy | VERACYTE INC | $4,620,000 | +17.1% | 918,556 | +25.7% | 1.03% | -25.4% |
| FBIO | Sell | FORTRESS BIOTECH INC | $3,569,000 | -13.9% | 1,326,636 | -0.8% | 0.79% | -45.2% |
| SRPT | Buy | SAREPTA THERAPUTICS INCcall | $2,603,000 | +29.8% | 624,600 | +103.1% | 0.58% | -17.4% |
| INNL | New | INNOCOLL HOLDINGS PLCsh | $2,579,000 | – | 468,148 | +100.0% | 0.57% | – |
| TRILLIUM THERAPEUTICS INC | $2,054,000 | -2.9% | 228,697 | 0.0% | 0.46% | -38.2% | ||
| SRPT | New | SAREPTA THERAPUTICS INCput | $2,006,000 | – | 1,332,000 | +100.0% | 0.45% | – |
| ONS | New | ONCOBIOLOGICS INC | $1,587,000 | – | 466,667 | +100.0% | 0.35% | – |
| New | PERNIX THERAPEUTICS HOLDINGS INCconvertible debt | $1,487,000 | – | 7,000,000 | +100.0% | 0.33% | – | |
| ASMB | New | ASSEMBLY BIOSCIENCES INC | $1,448,000 | – | 260,982 | +100.0% | 0.32% | – |
| CLLS | Buy | CELLECTIS - ADRsponsored ads | $1,135,000 | +65.0% | 42,671 | +70.7% | 0.25% | +5.0% |
| LJPC | Sell | LA JOLLA PHARMACEUTICAL CO | $1,120,000 | -74.7% | 70,000 | -66.9% | 0.25% | -83.9% |
| CRVS | CORVUS PHARMACEUTICALS INC | $1,067,000 | -1.7% | 74,800 | 0.0% | 0.24% | -37.5% | |
| VCEL | Sell | VERICEL CORP | $574,000 | -64.4% | 255,000 | -7.3% | 0.13% | -77.2% |
| NK | Sell | NANTKWEST INC | $450,000 | -71.9% | 72,412 | -62.8% | 0.10% | -82.1% |
| ONSIW | New | ONCOBIOLOGICS INC - WARRANT Awarrant | $107,000 | – | 233,333 | +100.0% | 0.02% | – |
| ONSIZ | New | ONCOBIOLOGICS INC - WARRANT Bwarrant | $105,000 | – | 233,333 | +100.0% | 0.02% | – |
| IMMU | New | IMMUNOMEDICS INCcall | $64,000 | – | 453,900 | +100.0% | 0.01% | – |
| Sell | ISh RUSSELL 2000 ETFput | $19,000 | -62.7% | 50,000 | -80.0% | 0.00% | -77.8% | |
| XON | Exit | INTREXON CORP.call | $0 | – | -200,000 | -100.0% | -0.02% | – |
| CBIO | Exit | CATALYST BIOSCIENCES INC. | $0 | – | -71,500 | -100.0% | -0.04% | – |
| Exit | SPDR SERIES TRUST - S&P BIOTECHput | $0 | – | -750,000 | -100.0% | -0.23% | – | |
| AEGR | Exit | AEGERION PHARMACEUTICALS INC | $0 | – | -306,800 | -100.0% | -0.40% | – |
| EGLTQ | Exit | EGALET CORPORATION. | $0 | – | -233,334 | -100.0% | -0.56% | – |
| PTX | Exit | PERNIX THERAPEUTICS HOLDINGS | $0 | – | -3,889,900 | -100.0% | -1.42% | – |
| ONTY | Exit | ONCOTHYREON INC | $0 | – | -4,069,072 | -100.0% | -1.80% | – |
| ANAC | Exit | ANACOR PHARMACEUTICALS INC | $0 | – | -166,700 | -100.0% | -3.11% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2016-08-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| AMICUS THERAPEUTICS INC | 36 | Q3 2023 | 17.9% |
| MIRATI THERAPEUTICS INC. | 35 | Q3 2023 | 17.2% |
| BIOMARIN PHARMACEUTICAL INC | 31 | Q3 2023 | 8.0% |
| SAREPTA THERAPUTICS INC | 28 | Q3 2023 | 14.8% |
| ASCENDIS PHARMA | 28 | Q3 2023 | 9.1% |
| ARGENX SE | 26 | Q3 2023 | 9.5% |
| IOVANCE BIOTHERAPEUTICS INC | 26 | Q3 2023 | 9.1% |
| FENNEC PHARMACEUTICALS INC | 25 | Q3 2023 | 0.4% |
| MADRIGAL PHARMACEUTICALS INC | 22 | Q3 2023 | 7.2% |
| XENON PHARMACEUTICALS INC | 22 | Q3 2023 | 3.3% |
View Avoro Capital Advisors LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Adverum Biotechnologies, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| DICE Therapeutics, Inc. | February 14, 2023 | 2,525,555 | 5.3% |
| IOVANCE BIOTHERAPEUTICS, INC. | February 14, 2023 | 7,020,000 | 4.4% |
| IVERIC bio, Inc. | February 14, 2023 | 6,750,000 | 5.0% |
| Kura Oncology, Inc. | February 14, 2023 | 3,105,000 | 4.5% |
| Aadi Bioscience, Inc. | September 26, 2022 | 2,849,402 | 11.7% |
| ARENA PHARMACEUTICALS INC | February 11, 2022 | 1,235,000 | 2.0% |
| AVADEL PHARMACEUTICALS PLC | February 11, 2022 | 1,670,000 | 2.9% |
| FENNEC PHARMACEUTICALS INC. | February 11, 2022 | 1,200,000 | 4.6% |
| POINT Biopharma Global Inc.Sold out | February 11, 2022 | 0 | 0.0% |
View Avoro Capital Advisors LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G/A | 2024-04-23 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Avoro Capital Advisors LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.